Wednesday, June 13, 2012

HL7 Offers Free Ambassador Webinar on Quality Reporting for Meaningful Use

Health Level Seven® International
For Immediate Release
Contact: Andrea Ribick
+1 (734) 677-7777

HL7 Offers Free Ambassador Webinar—Setting the Standard for Quality Reporting and Meaningful Use

          Ann Arbor, Michigan, USA – June 13, 2012 – Health Level Seven® International (HL7®), the global authority for interoperability and standards in healthcare information technology with members in 55 countries, will present a complimentary Ambassador webinar titled “Setting the Standard for Quality Reporting and Meaningful Use” on Monday, June 18, from 1:00 – 2:00 pm EDT.
Significant efforts are underway in the U.S. and elsewhere to develop an end-to-end approach to quality reporting from electronic health records.  This webinar will cover the latest on the evolving interoperability standards being developed by HL7 in support of quality reporting (including eMeasure, Quality Reporting Document Architecture, and Consolidated CDA).  It will provide an overview of these standards and discuss their relationship to proposed requirements for Meaningful Use of certified EHRs in the U.S. 
Bob Dolin, MD, FACP, president and chief medical officer at Lantana Consulting Group, vice chair of HL7 International, and co-chair of the HL7 Structured Documents Work Group, will be presenting the webinar. Dr. Dolin is a co-editor of both the CDA® standard and the CCD implementation guide. Dr. Dolin has also been the co-editor of many CDA-based implementation guides, including the greenCDA®.
          To register for this free webinar, please visit
          HL7 Ambassadors present standardized presentations about HL7 as speaker volunteers. They are available to present at local, regional or national conferences. Please contact HL7 at +1 (734) 677-7777 if you would like to schedule an HL7 Ambassador for an upcoming event.

About Health Level Seven International (HL7)
Founded in 1987, Health Level Seven International is the global authority for healthcare information interoperability and standards with affiliates established in more than 30 countries. HL7 is a non-profit, ANSI accredited standards development organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing, and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. HL7’s more than 2,300 members represent approximately 500 corporate members, which include more than 90 percent of the information systems vendors serving healthcare. HL7 collaborates with other standards developers and provider, payer, philanthropic and government agencies at the highest levels to ensure the development of comprehensive and reliable standards and successful interoperability efforts.

HL7’s endeavors are sponsored, in part, by the support of its benefactors: Abbott; Accenture; Allscripts; Booz Allen Hamilton; Centers for Disease Control and Prevention; Duke Translational Medicine Institute; Epic; European Medicines Agency; the Food and Drug Administration; GE Healthcare Information Technologies; GlaxoSmithKline; Hospital Corporation American (HCA); IBM; InterSystems Corporation; Kaiser Permanente; Lockheed Martin; McKesson Provider Technology; Microsoft Corporation; NICTIZ National Healthcare; Novartis; Oracle Corporation; Partners HealthCare System, Inc.; Pfizer, Inc.; Philips Healthcare; Quest Diagnostics Inc.; Siemens Healthcare; Thomson Reuters; the U.S. Department of Defense, Military Health System; and the U.S. Department of Veterans Affairs.

Numerous HL7 Affiliates have been established around the globe including Argentina, Australia, Austria, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Croatia, Czech Republic, Finland, France, Germany, Greece, Hong Kong, India, Italy, Japan, Korea, Luxembourg, Netherlands, New Zealand, Norway, Pakistan, Puerto Rico, Romania, Russia, Singapore, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, and Uruguay.

For more information, please visit:
# # #


Post a Comment